The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides is an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two recent decades. The feast of these reader-friendly reviews on topics of great scientific importance – many of which are considered significant medical breakthroughs, makes this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians. The second volume of this ebook series covers topics including: -Clear Cell Renal Cell Carcinoma as a Model of Pathological Angiogenesis -Discovery and Development of Antiangiogenetic Drugs in Ovarian Cancer -Anti-Angiogenic Therapy and Cardiovascular Diseases … and more.

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance – many of which are considered significant medical breakthroughs, makes this book excellent reading both for the novice as well as for expert medicinal chemists and clinicians. This volume brings together 5 reviews on these topics: -Beta-blockers for treating premature retinopathy -Anti-angiogenic activity of disintegrin-based, synthetic cyclic KTS peptides -Anti-angiogenic therapy of lung cancer -Oral anti-angiogenic therapy for NSCLC -Angiogenesis in hepatocellular carcinoma

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, wound healing disorders, etc. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance – many of which are considered significant medical breakthroughs, makes this series excellent reading both for the novice as well as for expert medicinal chemists and clinicians. This volume brings together 5 reviews on the following topics: - Retinal angiogenesis - Effects of brief daily EMF therapy on tumor growths - Evolution of the role of angiogenesis in cancer treatments over six decades - Anti-angiogenesis drugs - Anti-angiogenesis therapy for multiple sclerosis - Update on the link between angiogenesis and portal hypertension

The inhibition of angiogenesis is an effective mechanism of slowing down tumor growth and malignancies. The process of induction or pro-angiogenesis is highly desirable for the treatment of cardiovascular diseases, and wound healing disorders. Efforts to understand the molecular basis, both for inhibition and induction, have yielded fascinating results. Anti-angiogenesis Drug Discovery and Development provides an excellent compilation of well-written reviews on various aspects of the anti-angiogenesis process. These reviews have been contributed by leading practitioners in drug discovery science and highlight the major developments in this exciting field in the last two decades. The feast of these reader-friendly reviews on topics of great scientific importance – many of which are considered significant medical breakthroughs, makes this series excellent reading both for the novice as well as for expert medicinal chemists and clinicians. <p> The fifth volume brings together reviews on the following topics: <p> - Targeted therapy for tumor vasculature <p> - Anti-angiogenic therapy for breast and prostate cancers (including information updates on clinical trials) <p> - Microbe-based and other novel antiangiogenesis therapies such as chromene-based agents

This Ebook describes the applicability of diverse natural and synthetic biopolymers and their blends in drugs, vaccines and gene delivery. It would serve as a concise body of information on biopolymers for researchers, industries and students of pharmaceutical, chemical, engineering and biomedical sciences. Practical and theoretical concepts are presented in depth. Examples of yet untapped indigenous African polymers with drug delivery potentials are highlighted. Many natural biopolymers with excellent drug delivery properties have not been appropriately exploited because there is very concise body of information that would demonstrate their potential. This Ebook should prove to be an important resource to researchers in the field.

Low-income populations in developing regions of Africa, Asia and the Americas have been particularly injured by a group of tropical infections denominated neglected diseases. Compared to important illnesses, neglected diseases do not enjoy significant research funding and are not considerably important targets for the “Big Pharma” ventures in terms of development of new drugs, though these infections can make widespread diseases like AIDS more deadly. Despite affecting millions of people around the world, causing many deaths and having a significant limiting influence on the quality of life of affected people, the selection of new molecular targets and the development of more efficient drugs against those diseases is scarce. Furthermore, little detailed computational work on this subject has appeared. It should be kept in mind, however, that computers are an essential tool in modern medicinal chemistry. Currently, these powerful computational tools allow one to obtain insights on the interaction between enzyme-substrate, reaction mechanisms, statistical behavior of molecules and much more, at the molecular level, contributing significantly to solve problems in biological systems. Chemoinformatics: Directions Toward Combating Neglected Diseases explores an open problem in academic literature with a stimulating discussion on the state of the art knowledge in this important research field with respect to neglected diseases, pointing out perspectives on using molecular modeling and theoretical approaches. This eBook is a handy reference guide for anyone who is interested in or deals with medicinal chemistry focused on neglected diseases, from students to advanced researchers.

Fast Dissolving/Disintegrating Dosage Forms (FDDFs) have been commercially available since the late 1990s. FDDFs were initially available as orodispersible tablets, and later, as orodipsersible films for treating specific populations (pediatrics, geriatrics, and psychiatric patients). Granules, pellets and mini tablets are among latest additions to these dosage forms, which are still in the development pipeline. As drug delivery systems, FDDFs enable quicker onset of action, immediate drug delivery, and sometimes offer bioavailability benefits due to buccal/sublingual absorption. With time, FDDF have evolved to deliver drugs in a sustained and controlled manner. Their current market and application is increasing in demands with advances in age adapted dosage forms for different patients and changing regulatory requirements that warrant mandatory assessments of new drugs and drug products before commercial availability. This book presents detailed information about FDDFs from their inception to recent developments. Readers will learn about the technical details of various FDDF manufacturing methods, formulation aspects, evaluation and methods to conduct clinical studies. The authors also give examples of marketed fast disintegrating/dissolving drug products in US, Europe, Japan, and India. This reference is ideal for pharmacology students at all levels seeking information about this specific form of drug delivery and formulation.

This e-book provides an overview of current technologies used to increase the topical/transdermal delivery of drugs, its protocols, advantages and limitations. It includes exclusive chapters on chemical enhancers, Iontophoresis, Sonophoresis, Electroporation, Microneedles and the more recent use of micro/nanoparticles to deliver drugs throughout the skin. The e-book's generalized approach on the topic is aimed to be helpful in drug discovery, drug delivery and toxicological research and to provide a broader perspective on the topic to readers with respect to current literature available on the subject. The book is an interesting source of information for pharmacy students, and pharmaceutical research and development units of universities and commercial industries.

This volume covers the methods of using skin penetrating agents, the therapeutic applications of physical penetration enhancers and devices in the market. Chapters cover topics such as transdermal drug delivery through iontophoresis, gene therapy, physiotherapy, skin disorders, vaccination, and pharmacology. Devices covered in this volume include micro needles, nano-carrier and gene delivery systems. This volume is a handy resource for professionals in medicine (dermatologists), biopharmacy, pharmaceutical technology, drug design and development (scientists and pharmaceutical R&D executives).